Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography

Objectives. The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves’ ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT). Methods. The right eyes of 36 patients (27 females and 9 males) with Graves’ ophthalmopathy (GO) and those of...

Full description

Saved in:
Bibliographic Details
Main Authors: Nan Yu, Yadi Zhang, Lei Kang, Ying Gao, Junqing Zhang, Yuan Wu
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2018/3529395
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558059217485824
author Nan Yu
Yadi Zhang
Lei Kang
Ying Gao
Junqing Zhang
Yuan Wu
author_facet Nan Yu
Yadi Zhang
Lei Kang
Ying Gao
Junqing Zhang
Yuan Wu
author_sort Nan Yu
collection DOAJ
description Objectives. The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves’ ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT). Methods. The right eyes of 36 patients (27 females and 9 males) with Graves’ ophthalmopathy (GO) and those of 36 age-, gender-, and diopter-level-matched healthy participants were evaluated. The patients’ data were obtained within 3 months after the onset of Graves’ disease (GD). Thyroid hormone levels and thyroid-stimulating hormone receptor antibody (TRAb) levels were measured, and the degree of exophthalmos was measured in all patients. Activity is measured by the clinical activity score (CAS). A horizontal scan centered on the fovea was performed in all participants. Five points of choroidal thickness were measured at the fovea (SFCT) and at 1500 μm nasal (N1500), 3000 μm nasal (N3000), 1500 μm temporal (T1500), and 3000 μm temporal (T3000) to the fovea. Results. The CT measurements obtained were (mean ± SD) 313.47 ± 100.32 μm, 279.22 ± 85.80 μm, 214.64 ± 75.52 μm, 313.19 ± 80.36 μm, and 298.14 ± 82.75 μm in patients with GO and were 256.33 ± 50.18 μm, 223.14 ± 59.61 μm, 176.69 ± 60.66 μm, 250.92 ± 52.184 μm, and 239.47 ± 60.35 μm in the control group at the foveal, N1500, N3000, T1500, and T3000 measurement points, respectively. The CT in GO patients was significantly increased at all the points compared with the control group (P<0.05). There was no relationship between the CT and CAS, the degree of exophthalmos, triiodothyronine (T3), tetraiodothyronine (T4), thyroid-stimulating hormone (TSH), or TRAb levels in GO. Conclusions. CT was found to be increased in GO patients and had poor relationship with CAS, exophthalmos, and thyroid function tests.
format Article
id doaj-art-b4439391e4894ec7a51a65f7c3d597d4
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-b4439391e4894ec7a51a65f7c3d597d42025-02-03T01:33:20ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/35293953529395Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence TomographyNan Yu0Yadi Zhang1Lei Kang2Ying Gao3Junqing Zhang4Yuan Wu5Department of Endocrinology, First Hospital, Peking University, Beijing, ChinaDepartment of Ophthalmology, First Hospital, Peking University, Beijing, ChinaDepartment of Ophthalmology, First Hospital, Peking University, Beijing, ChinaDepartment of Endocrinology, First Hospital, Peking University, Beijing, ChinaDepartment of Endocrinology, First Hospital, Peking University, Beijing, ChinaDepartment of Ophthalmology, First Hospital, Peking University, Beijing, ChinaObjectives. The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves’ ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT). Methods. The right eyes of 36 patients (27 females and 9 males) with Graves’ ophthalmopathy (GO) and those of 36 age-, gender-, and diopter-level-matched healthy participants were evaluated. The patients’ data were obtained within 3 months after the onset of Graves’ disease (GD). Thyroid hormone levels and thyroid-stimulating hormone receptor antibody (TRAb) levels were measured, and the degree of exophthalmos was measured in all patients. Activity is measured by the clinical activity score (CAS). A horizontal scan centered on the fovea was performed in all participants. Five points of choroidal thickness were measured at the fovea (SFCT) and at 1500 μm nasal (N1500), 3000 μm nasal (N3000), 1500 μm temporal (T1500), and 3000 μm temporal (T3000) to the fovea. Results. The CT measurements obtained were (mean ± SD) 313.47 ± 100.32 μm, 279.22 ± 85.80 μm, 214.64 ± 75.52 μm, 313.19 ± 80.36 μm, and 298.14 ± 82.75 μm in patients with GO and were 256.33 ± 50.18 μm, 223.14 ± 59.61 μm, 176.69 ± 60.66 μm, 250.92 ± 52.184 μm, and 239.47 ± 60.35 μm in the control group at the foveal, N1500, N3000, T1500, and T3000 measurement points, respectively. The CT in GO patients was significantly increased at all the points compared with the control group (P<0.05). There was no relationship between the CT and CAS, the degree of exophthalmos, triiodothyronine (T3), tetraiodothyronine (T4), thyroid-stimulating hormone (TSH), or TRAb levels in GO. Conclusions. CT was found to be increased in GO patients and had poor relationship with CAS, exophthalmos, and thyroid function tests.http://dx.doi.org/10.1155/2018/3529395
spellingShingle Nan Yu
Yadi Zhang
Lei Kang
Ying Gao
Junqing Zhang
Yuan Wu
Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography
Journal of Ophthalmology
title Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography
title_full Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography
title_fullStr Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography
title_full_unstemmed Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography
title_short Analysis in Choroidal Thickness in Patients with Graves’ Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography
title_sort analysis in choroidal thickness in patients with graves ophthalmopathy using spectral domain optical coherence tomography
url http://dx.doi.org/10.1155/2018/3529395
work_keys_str_mv AT nanyu analysisinchoroidalthicknessinpatientswithgravesophthalmopathyusingspectraldomainopticalcoherencetomography
AT yadizhang analysisinchoroidalthicknessinpatientswithgravesophthalmopathyusingspectraldomainopticalcoherencetomography
AT leikang analysisinchoroidalthicknessinpatientswithgravesophthalmopathyusingspectraldomainopticalcoherencetomography
AT yinggao analysisinchoroidalthicknessinpatientswithgravesophthalmopathyusingspectraldomainopticalcoherencetomography
AT junqingzhang analysisinchoroidalthicknessinpatientswithgravesophthalmopathyusingspectraldomainopticalcoherencetomography
AT yuanwu analysisinchoroidalthicknessinpatientswithgravesophthalmopathyusingspectraldomainopticalcoherencetomography